• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Republica Press

Your Business & Political News Source

REPUBLICA PRESS
Your Business & Political News Source

  • Home
  • BUSINESS
  • MONEY
  • POLITICS
  • REAL ESTATE
  • SCIENCE/TECH
  • US
  • WORLD
  • VIDEOS

AstraZeneca’s Covid-19 vaccine has generated $275 million in sales so far this year.

by

The Covid-19 vaccine developed by AstraZeneca and the University of Oxford brought in $275 million in sales from about 68 million doses delivered in the first three months of this year, AstraZeneca reported on Friday.

AstraZeneca disclosed the figure, most of which came from sales in Europe, as it reported its first-quarter financial results. It offers the clearest view to date of how much money is being brought in by one of the leading Covid vaccines.

AstraZeneca, which has pledged not to profit on its vaccine during the pandemic, has been selling the shot to governments for several dollars per dose, less expensive than the other leading vaccines. The vaccine has won authorization in at least 78 countries since December but is not approved for use in the United States.

The Covid vaccine represented just under 4 percent of AstraZeneca’s revenue for the quarter; it was nowhere near the company’s biggest revenue generator. By comparison, the company’s best-selling product, the cancer drug Tagrisso, brought in more than $1.1 billion in sales in the quarter.

said this week that it would make available to the rest of the world up to 60 million doses of its supply of AstraZeneca shots, pending a review of their quality.

If the company does win authorization from the U.S. Food and Drug Administration, it could help shore up confidence in a vaccine whose reputation been hit by concerns about a rare but serious side effect involving blood clotting. The F.D.A.’s evaluation process is considered the gold standard globally.

Johnson & Johnson, whose vaccine was authorized for emergency use at the end of February, reported last week that its vaccine generated $100 million in sales in the United States in the first three months of the year. The federal government is paying the company $10 a dose. Like AstraZeneca, Johnson & Johnson has pledged to sell its vaccine “at cost” — meaning it won’t profit on the sales — during the pandemic.

Vaccines from Pfizer and Moderna cost more, and neither company has said that it will forego profits. Pfizer has said that it expects its vaccine to bring in about $15 billion in revenue this year; Moderna said it anticipates $18.4 billion in sales.

Both companies are scheduled to report their first-quarter results next week.

View Source

Filed Under: BUSINESS Tagged With: AstraZeneca, AstraZeneca PLC, Biden administration, Cancer, Coronavirus (2019-nCoV), COVID-19, Europe, Food, Food and Drug Administration, Gold, Government, internal-essential, Money, Oxford University, Pfizer, United States, Vaccination and Immunization

Primary Sidebar

More to See

‘Everybody Is Armed’: As Shootings Soar, Philadelphia Is Awash in Guns

There were no arrests in three quarters of last year’s fatal shootings, according to statistics provided by Mr. Krasner’s office, even as arrests for … [Read More...] about ‘Everybody Is Armed’: As Shootings Soar, Philadelphia Is Awash in Guns

$5.45 Million Sale of 25-Unit Highland Park Community in Los Angeles, CA, Arranged by The Mogharebi Group

COSTA MESA, Calif.--(BUSINESS WIRE)--The Mogharebi Group ("TMG") has arranged the $5.45 million sale of San Pascual, a 25-unit community located in … [Read More...] about $5.45 Million Sale of 25-Unit Highland Park Community in Los Angeles, CA, Arranged by The Mogharebi Group

GM reveals new GMC Canyon premium midsize pickup, starting at $40,000

2023 GMC Canyon DenaliGMDETROIT — General Motors on Thursday revealed its redesigned GMC Canyon as a more premium offering than the current midsize … [Read More...] about GM reveals new GMC Canyon premium midsize pickup, starting at $40,000

Copyright © 2022 · Republica Press · Log in · As an Amazon Associate we earn from qualifying purchases.

Terms and Conditions - Privacy Policy